BACKGROUND:Glucose-insulin-potassium (GIK) administration is advocated on the premise of preventing hyperglycaemia and hyperlipidaemia during reperfusion after cardiac interventions. Current research has focused on hyperglycaemia, largely ignoring lipids, or other substrates. The present study examines lipids and other substrates during and after on-pump coronary artery bypass grafting and how they are affected by a hyperinsulinaemic normoglycaemic clamp. METHODS: Forty-four patients were randomized to a control group (n=21) or to a GIK group (n=23) receiving a hyperinsulinaemic normoglycaemic clamp during 26 h. Plasma levels of free fatty acid (FFA), total and lipoprotein (VLDL, HDL, and LDL)-triglycerides (TG), ketone bodies, and lactate were determined. RESULTS: In the control group, mean FFA peaked at 0.76 (sem 0.05) mmol litre(-1) at early reperfusion and decreased to 0.3-0.5 mmol litre(-1) during the remaining part of the study. GIK decreased FFA levels to 0.38 (0.05) mmol litre(-1) at early reperfusion, and to low concentrations of 0.10 (0.01) mmol litre(-1) during the hyperinsulinaemic clamp. GIK reduced the area under the curve (AUC) for FFA by 75% and for TG by 53%. The reduction in total TG was reflected by a reduction in the VLDL (-54% AUC) and HDL (-42% AUC) fraction, but not in the LDL fraction. GIK prevented the increase in ketone bodies after reperfusion (-44 to -47% AUC), but was without effect on lactate levels. CONCLUSIONS:Mild hyperlipidaemia was only observed during early reperfusion (before heparin reversal) and the hyperinsulinaemic normoglycaemic clamp actually resulted in hypolipidaemia during the largest part of reperfusion after cardiac surgery.
RCT Entities:
BACKGROUND:Glucose-insulin-potassium (GIK) administration is advocated on the premise of preventing hyperglycaemia and hyperlipidaemia during reperfusion after cardiac interventions. Current research has focused on hyperglycaemia, largely ignoring lipids, or other substrates. The present study examines lipids and other substrates during and after on-pump coronary artery bypass grafting and how they are affected by a hyperinsulinaemic normoglycaemic clamp. METHODS: Forty-four patients were randomized to a control group (n=21) or to a GIK group (n=23) receiving a hyperinsulinaemic normoglycaemic clamp during 26 h. Plasma levels of free fatty acid (FFA), total and lipoprotein (VLDL, HDL, and LDL)-triglycerides (TG), ketone bodies, and lactate were determined. RESULTS: In the control group, mean FFA peaked at 0.76 (sem 0.05) mmol litre(-1) at early reperfusion and decreased to 0.3-0.5 mmol litre(-1) during the remaining part of the study. GIK decreased FFA levels to 0.38 (0.05) mmol litre(-1) at early reperfusion, and to low concentrations of 0.10 (0.01) mmol litre(-1) during the hyperinsulinaemic clamp. GIK reduced the area under the curve (AUC) for FFA by 75% and for TG by 53%. The reduction in total TG was reflected by a reduction in the VLDL (-54% AUC) and HDL (-42% AUC) fraction, but not in the LDL fraction. GIK prevented the increase in ketone bodies after reperfusion (-44 to -47% AUC), but was without effect on lactate levels. CONCLUSIONS: Mild hyperlipidaemia was only observed during early reperfusion (before heparin reversal) and the hyperinsulinaemic normoglycaemic clamp actually resulted in hypolipidaemia during the largest part of reperfusion after cardiac surgery.
Authors: Sylas B Cappi; Danilo T Noritomi; Irineu T Velasco; Rui Curi; Tatiana C A Loureiro; Francisco G Soriano Journal: Intensive Care Med Date: 2012-02-02 Impact factor: 17.440
Authors: Garrett R Mullins; Lifu Wang; Vidisha Raje; Samantha G Sherwood; Rebecca C Grande; Salome Boroda; James M Eaton; Sara Blancquaert; Pierre P Roger; Norbert Leitinger; Thurl E Harris Journal: Proc Natl Acad Sci U S A Date: 2014-11-24 Impact factor: 11.205
Authors: Michael A Puskarich; Michael S Runyon; Stephen Trzeciak; Jeffrey A Kline; Alan E Jones Journal: J Clin Pharmacol Date: 2009-05-05 Impact factor: 3.126
Authors: A Hunyadi; E Liktor-Busa; A Márki; A Martins; N Jedlinszki; T J Hsieh; M Báthori; J Hohmann; I Zupkó Journal: Evid Based Complement Alternat Med Date: 2013-12-05 Impact factor: 2.629
Authors: Rianne Nederlof; Nina C Weber; Nicole P Juffermans; Bas A M J de Mol; Markus W Hollmann; Benedikt Preckel; Coert J Zuurbier Journal: BMC Anesthesiol Date: 2017-03-29 Impact factor: 2.217
Authors: Coert J Zuurbier; Luc Bertrand; Christoph R Beauloye; Ioanna Andreadou; Marisol Ruiz-Meana; Nichlas R Jespersen; Duvaraka Kula-Alwar; Hiran A Prag; Hans Eric Botker; Maija Dambrova; Christophe Montessuit; Tuuli Kaambre; Edgars Liepinsh; Paul S Brookes; Thomas Krieg Journal: J Cell Mol Med Date: 2020-05-08 Impact factor: 5.310
Authors: Charissa E van den Brom; Carolien Se Bulte; Stephan A Loer; R Arthur Bouwman; Christa Boer Journal: Cardiovasc Diabetol Date: 2013-03-04 Impact factor: 9.951